In recognition of our win for the TOGETHER Trial, we honor our legacy and congratulate leaders involved in the CHAP trial to be recognized at this year’s Society for Clinical Trials conference.
Purpose Life Sciences, a global impact research organization, is delighted to announce that it was honored with the esteemed David Sackett Trial of the Year Award in 2022 by the Society for Clinical Trials (SCT). This prestigious recognition, given to the best randomized clinical trial published in the previous year, serves as a testament to the hard work, dedication, and unwavering commitment of our team to excellence in adaptive platform trials.
The David Sackett Annual Trial of the Year Award was given to Purpose Life Science in 2022 for its outstanding contributions to the 2021 TOGETHER Trial, the world’s largest placebo-controlled clinical trial for the evaluation of COVID-19 therapeutics. The TOGETHER Trial consists of 22 sites across Brazil, where patients are being treated with a range of potential new COVID-19 therapeutic agents. The aim is to give these potential therapies at the early stages of infection, to prevent more serious complications or death. The development of effective vaccines against the COVID-19 virus holds tremendous potential to slow and eventually halt this pandemic altogether. Unfortunately, access to vaccines in low and middle-income countries is a challenge, and people are suffering as a consequence. This reality makes the need for effective treatments in the early stages of infection all the more important.
“In winning the 2022 David Sackett Trial of the Year Award, we are humbled and grateful to have been chosen from a pool of highly accomplished contenders, and we extend our deepest appreciation to the judges and the Society for Clinical Trials for this remarkable honor,” said Dr. Ed Mills, Founder and CEO of Purpose Life Sciences. “Moreover, this award recognition stands as a validation of our pursuit of excellence and steadfast dedication to delivering innovative value to our clients and patients worldwide.”
As we celebrate this milestone, we would also like to extend our warmest congratulations to the 2023 awardee, The Chronic Hypertension and Pregnancy (CHAP) Trial, which evaluated the effects of prescribing blood pressure medication to pregnant people with mild chronic hypertension. With over 2,408 randomized participants at 61 US sites, CHAP is the largest and most diverse study of its kind. Accepting the award is Dr. Alan T. Tita, Senior Vice Chair for Research and Innovation, Department of Obstetrics and Gynecology, Center for Women’s Reproductive Health, Mamix E. Heersink School of Medicine at the University of Alabama at Birmingham. As he approaches the stage to share more about CHAP’s work, we eagerly anticipate learning about their accomplishments and applaud their hard work.
Dr. Mills continued, “At Purpose Life Sciences, we firmly believe that recognition is not a solitary pursuit but rather a celebration of the collective efforts of the entire industry. It is through acknowledging outstanding achievements and inspiring one another that we propel our industry forward, setting new benchmarks and raising the bar for excellence.”
Purpose Life Sciences is proud to be part of an industry that fosters innovation, collaboration, and relentless pursuit of success. We offer our heartfelt congratulations to the entire team involved in the CHAP trial, and we look forward to their continued contributions to our vibrant industry.